Ventiv Health Inc announced a sales and marketing agreement with Metagen Pharmaceuticals to provide strategic marketing and sales force services for Prosed/DS, for the treatment of urinary tract infections. Under the terms of the agreement, Ventiv Health will provide national sales and marketing support, targeting OBGYN offices through its VenFemme sales organization. Prosed/DS will also be promoted to the medical community in Puerto Rico. Promotech, a Colorado based subsidiary of Ventiv, will provide tele-detailing services to OBGYN offices in support of Prosed/DS as well.
"Ventiv's integrated services and seamless execution will provide valuable contribution to the growth of Prosed/DS," stated Jerry Finley, CEO, Metagen Pharmaceuticals.
"This agreement demonstrates Ventiv's commitment to provide customized solutions for specialty pharmaceutical companies," commented Terry Herring, President, Ventiv Health U.S. Sales. "We are delighted to add Metagen Pharmaceuticals to our growing list of client partnerships and look forward to continued success."
Prosed/DS is a combination formulation of several time tested urologic drugs designed to act in concert to deliver rapid relief of pain and spasm of the lower urinary tract due to inflammation, diagnostic procedures and in the treatment of cystitis, urethritis, and trigonitis.